Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Application of aluminum chloride phthalocyanine-loaded solid lipid nanoparticles for photodynamic inactivation of melanoma cells

Full text
Goto, Patricia L. ; Siqueira-Moura, Marigilson P. ; Tedesco, Antonio C.
Total Authors: 3
Document type: Journal article
Source: International Journal of Pharmaceutics; v. 518, n. 1-2, p. 228-241, FEB 25 2017.
Web of Science Citations: 12

Cutaneous melanoma is the most aggressive skin cancer and is particularly resistant to current therapeutic approaches. Photodynamic therapy (PDT) is a well-established photoprocess that is employed to treat some cancers, including non-melanoma skin cancer. Aluminum chloride phthalocyanine (CIAIPc) is used as a photosensitizer in PDT; however, its high hydrophobicity hampers its photodynamic activity under physiological conditions. The aim of this study was to produce solid lipid nanoparticles (SLN) containing CIAIPc using the direct emulsification method. CIAIPc-loaded SLNs (CIAIPc/SLNs) were characterized according to their particle size and distribution, zeta potential, morphology, encapsulation efficiency, stability, and phototoxic action in vitro in B16-F10 melanoma cells. CIAIPc/SLN had a mean diameter between 100 and 200 nm, homogeneous size distribution (polydispersity index <0.3), negative zeta potential, and spherical morphology. The encapsulation efficiency was approximately 100%. The lipid crystallinity was investigated using X-ray diffraction and differential scanning calorimetry and indicated that CIAIPc was integrated into the SLN matrix. The CIAIPc/SLN formulations maintained their physicochemical stability without expelling the drug over a 24-month period. Compared to free CIAIPc, CIAIPc/SLN exerted outstanding phototoxicity effects in vitro against melanoma cells. Therefore, our results demonstrated that the CIAIPc/SLN described in the current study has the potential for use in further preclinical and clinical trials in PDT for melanoma treatment. (C) 2017 Elsevier B.V. All rights reserved. (AU)

FAPESP's process: 13/50181-1 - Use of drugs containing nanocarriers with photosensitizers and/or other active compounds applied to cell therapy and treatment of central nervous system disorders
Grantee:Antonio Claudio Tedesco
Support type: Research Projects - Thematic Grants